Amineptine (Survector, Maneon, Directim, Neolior, Provector, Viaspera) is an atypical tricyclic antidepressant (TCA) that selectively inhibits the reuptake of dopamine and to a lesser extent norepinephrine, thus exerting a powerful and fast-acting antidepressant effect.
Introduced in France in 1978 by the pharmaceutical giant Servier and marketed under the trade name Survector, amineptine soon gained a reputation for abuse due to its short-lived,...
more
Amineptine (Survector, Maneon, Directim, Neolior, Provector, Viaspera) is an atypical tricyclic antidepressant (TCA) that selectively inhibits the reuptake of dopamine and to a lesser extent norepinephrine, thus exerting a powerful and fast-acting antidepressant effect.
Introduced in France in 1978 by the pharmaceutical giant Servier and marketed under the trade name Survector, amineptine soon gained a reputation for abuse due to its short-lived, but pleasant, stimulant effect experienced by some patients. (This is to be distinguished from its antidepressant effect, which appears in approximately 7 days after commencing treatment.) This led to the Food and Drug Administration suspending the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until 2005.
Currently amineptine is off-patent and very difficult to obtain. Rare cases of hepatotoxicity, some serious, have been reported, but...
less
